01 2BRISTOL
02 42GILEAD SCIENCES INC
03 22JANSSEN PRODS
01 310039718*PED
02 27176220
03 27700645
04 610039718
05 110786518
06 27176220*PED
07 27390791
08 17390791*PED
09 27635704
10 27635704*PED
11 17700645*PED
12 128148374
13 38148374*PED
14 28518987
15 18518987*PED
16 18592397
17 28633219
18 28633219*PED
19 18716264
20 38754065
21 18754065*PED
22 28981103
23 28981103*PED
24 39296769
25 19296769*PED
26 19457036
27 19744181
28 29891239
29 29891239*PED
01 30Y
02 36Blank
01 44Y
02 22Blank
01 42024-01-13
02 22024-02-16
03 12024-08-16
04 22025-04-17
05 12025-10-17
06 22026-08-27
07 42026-10-26
08 22026-12-26
09 22027-02-27
10 42027-04-26
11 12027-06-26
12 142029-09-03
13 52030-03-03
14 22030-04-30
15 22030-10-30
16 62032-08-15
17 62032-10-06
18 22033-02-15
19 32033-04-06
20 12038-07-19
Patent Expiration Date : 2029-09-03
ATAZANAVIR SULFATE; COBICISTAT
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 206353
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-10-06
ATAZANAVIR SULFATE; COBICISTAT
US Patent Number : 10039718
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 206353
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-10-06
Patent Expiration Date : 2030-04-30
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8633219
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2030-04-30
Patent Expiration Date : 2026-10-26
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 7635704
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2026-10-26
Patent Expiration Date : 2024-01-13
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 8716264
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2029-09-03
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203094
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2029-09-03
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8148374
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-1279
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2029-09-03
Patent Expiration Date : 2032-08-15
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US Patent Number : 8754065
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 207561
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2032-08-15
Patent Expiration Date : 2024-01-13
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 9457036
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
Patent Expiration Date : 2024-01-13
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US Patent Number : 9744181
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 203100
Patent Use Code : U-257
Delist Requested :
Patent Use Description : TREATMENT OF HIV INFEC...
Patent Expiration Date : 2024-01-13
LOOKING FOR A SUPPLIER?
Market Place
